Last reviewed · How we verify
placebo to tocilizumab SC
Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response by blocking the action of interleukin-6.
Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response by blocking the action of interleukin-6. Used for Rheumatoid arthritis, Juvenile idiopathic arthritis, Cytokine release syndrome.
At a glance
| Generic name | placebo to tocilizumab SC |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | IL-6 receptor antagonist |
| Target | IL-6R |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Tocilizumab works by binding to the interleukin-6 receptor, preventing the binding of interleukin-6 and thus inhibiting the inflammatory response. This results in reduced inflammation and swelling in the body. Tocilizumab is used to treat various inflammatory conditions, including rheumatoid arthritis and cytokine release syndrome.
Approved indications
- Rheumatoid arthritis
- Juvenile idiopathic arthritis
- Cytokine release syndrome
Common side effects
- Increased risk of infections
- Neutropenia
- Thrombocytopenia
- Hypersensitivity reactions
Key clinical trials
- Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement (PHASE3)
- Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy (PHASE2)
- An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy (PHASE3)
- A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc) (PHASE3)
- An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) (PHASE3)
- A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX (PHASE3)
- To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) (PHASE3)
- A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo to tocilizumab SC CI brief — competitive landscape report
- placebo to tocilizumab SC updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI